secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-05-11T20:10:24+00:00
Accession:  0001213900-26-054480
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics Q1 net loss $971K; Phase 2 AD trial on track, topline mid-2026
--------------------------------------------------------------------------------

- Cash and equivalents $11.2M as of March 31, 2026, up from $5.1M at Dec 31, 2025.
- Net loss $970,972 ($0.03 basic EPS) vs $328,547 ($0.01) in Q1 2025.
- G&A expenses $1.1M, R&D $109K; total op expenses $1.25M.
- Avenue Capital facility provides up to $25M; initial $7M funded March 24, 2026; $18M available on milestones.
- Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis; interim analysis Q2 2026, topline mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026054480/0001213900-26-054480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026054480/ea0289856-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-054480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer